News Brief
Government Readies Two More Labs For Covid Vaccine Testing From PM CARES Fund
DBT-NIAB Central Drugs Laboratory for COVID-19 Vaccine Testing (Image Credits: PIB)
In a significant step, two more Central Drug Laboratories have been readied at Pune and Hyderabad for Covid vaccine testing. The step has been taken in the wake of the Covid-19 pandemic, and considering the enhanced production of Covid vaccines in the country.
Currently, India has a Central Drugs Laboratory (CDL) at Kasauli, which is the National Control Laboratory for testing and pre-release certification of immunobiologicals (vaccines and antisera) meant for human use in India.
According to a Science & Technology Ministry statement, the facility at the National Centre for Cell Science, Pune, has now been notified as a Central Drugs Laboratory for testing and lot release of Covid-19 vaccines, through a gazette notification issued by the Health & Family Welfare Ministry on June 28.
The facility at the National Institute of Animal Biotechnology, Hyderabad is likely to receive necessary notification shortly, it said.
"With generous support from PM CARES Fund trust in a very short span of time, both the institutions, through relentless efforts, have set up the state-of-the-art modern facilities for this purpose.
"The facilities are expected to test approx 60 batches of vaccines per month. The facilities are geared up to test existing Covid-19 vaccines and other newer Covid-19 vaccines as per demand of the nation. This will not only expedite the vaccine manufacture and supply but also be logistically convenient considering that both Pune and Hyderabad are the two vaccine manufacturing hubs," the statement said.
The Department of Biotechnology, under the Science & Technology Ministry, now has set up facilities in its autonomous research institutes, the NCCS, and the NIAB, for batch testing and quality control of vaccines.
Since the COVID-19 pandemic, Department of Biotechnology has been in the forefront contributing to various COVID-19 related activities including Vaccine Development, Diagnostics and testing, bio-banking and genomic surveillance, in addition to fundamental research and also building a strong ecosystem for translational research
DBT-NCCS and DBT-NIAB have been the pillars for many aspects of infectious disease related work in India and have contributed to advancement of cutting-edge research output in frontier areas of Biotechnology relevant to human health and disease.
With IANS Inputs
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
